Dietary supplements : a framework for evaluating safety

著者

    • Institute of Medicine (U.S.). Committee on the Framework for Evaluating the Safety of Dietary Supplements

書誌事項

Dietary supplements : a framework for evaluating safety

Institute of Medicine and National Research Council, Committee on the Framework for Evaluating the Safety of Dietary Supplements, Food and Nutrition Board, Board on Life Sciences

National Academies Press, c2005

  • : hardcover

大学図書館所蔵 件 / 全22件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

HTTP:URL=http://www.loc.gov/catdir/toc/ecip051/2004022339.html Information=Table of contents

内容説明・目次

内容説明

The growing consumer interest in health and fitness has expanded the market for a wide range of products, from yoga mats to the multiple dietary supplements now on the market. Supplements are popular, but are they safe? Many dietary supplements are probably safe when used as recommended. However, since 1994 when Congress decided that they should be regulated as if they were foods, they are assumed to be safe unless the Food and Drug Administration can demonstrate that they pose a significant risk to the consumer. But there are many types of products that qualify as dietary supplements, and the distinctions can become muddled and vague. Manufacturers are not legally required to provide specific information about safety before marketing their products. And the sales of supplements have been steadily increasing?all together, the various types now bring in almost $16 billion per year. Given these confounding factors, what kind of information can the Food and Drug Administration use to effectively regulate dietary supplements? This book provides a framework for evaluating dietary supplement safety and protecting the health of consumers. Table of Contents Front Matter Executive Summary 1 Introduction and Background 2 Approaches Used by Others and Existing Safety Frameworks 3 The Framework 4 Categories of Scientific Evidence--Human Information and Data 5 Categories of Scientific Evidence--Animal Data 6 Categories of Scientific Evidence--Information About Related Substances 7 Categories of Scientific Evidence--In Vitro Data 8 Interactions 9 Vulnerable Groups and Prevalance of Use 10 Scientific Principles for Integrating and Evaluating the Available Data 11 Applying the Framework: Case Studies Using the Prototype Safety Monographs 12 Factors Influencing Use of the Safety Framework 13 Findings and Recommendations Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances Appendix B: Scope of Work and Comments to Initial July 2002 Framework Appendix C: Plant Family Information Appendix D: Chaparral: Prototype Monograph Summary Appendix E: Glucosamine: Prototype Monograph Summary Appendix F: Melatonin: Prototype Monograph Summary Appendix G: Chromium Picolinate: Prototype Monograph Summary Appendix H: Saw Palmetto: Prototype Monograph Summary Appendix I: Shark Cartilage: Prototype Monograph Summary Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women Appendix L: Acknowledgements Appendix M: Biographical Sketches of Commitee Members Index

目次

  • 1 Front Matter
  • 2 Executive Summary
  • 3 1 Introduction and Background
  • 4 2 Approaches Used by Others and Existing Safety Frameworks
  • 5 3 The Framework
  • 6 4 Categories of Scientific Evidence--Human Information and Data
  • 7 5 Categories of Scientific Evidence--Animal Data
  • 8 6 Categories of Scientific Evidence--Information About Related Substances
  • 9 7 Categories of Scientific Evidence--In Vitro Data
  • 10 8 Interactions
  • 11 9 Vulnerable Groups and Prevalance of Use
  • 12 10 Scientific Principles for Integrating and Evaluating the Available Data
  • 13 11 Applying the Framework: Case Studies Using the Prototype Safety Monographs
  • 14 12 Factors Influencing Use of the Safety Framework
  • 15 13 Findings and Recommendations
  • 16 Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances
  • 17 Appendix B: Scope of Work and Comments to Initial July 2002 Framework
  • 18 Appendix C: Plant Family Information
  • 19 Appendix D: Chaparral: Prototype Monograph Summary
  • 20 Appendix E: Glucosamine: Prototype Monograph Summary
  • 21 Appendix F: Melatonin: Prototype Monograph Summary
  • 22 Appendix G: Chromium Picolinate: Prototype Monograph Summary
  • 23 Appendix H: Saw Palmetto: Prototype Monograph Summary
  • 24 Appendix I: Shark Cartilage: Prototype Monograph Summary
  • 25 Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral
  • 26 Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women
  • 27 Appendix L: Acknowledgements
  • 28 Appendix M: Biographical Sketches of Commitee Members
  • 29 Index

「Nielsen BookData」 より

詳細情報

ページトップへ